Grek CL - Search Results

1

Connexin 43-Based Therapeutics for Dermal Wound Healing.

Montgomery J, Ghatnekar GS, Grek CL, Moyer KE, Gourdie RG. Montgomery J, et al. Among authors: grek cl. Int J Mol Sci. 2018 Jun 15;19(6):1778. doi: 10.3390/ijms19061778. Int J Mol Sci. 2018. PMID: 29914066 Free PMC article. Review.

2

Cardiac to cancer: connecting connexins to clinical opportunity.

Grek CL, Rhett JM, Ghatnekar GS. Grek CL, et al. FEBS Lett. 2014 Apr 17;588(8):1349-64. doi: 10.1016/j.febslet.2014.02.047. Epub 2014 Mar 4. FEBS Lett. 2014. PMID: 24607540 Free PMC article. Review.

3

The effect of a connexin43-based Peptide on the healing of chronic venous leg ulcers: a multicenter, randomized trial.

Ghatnekar GS, Grek CL, Armstrong DG, Desai SC, Gourdie RG. Ghatnekar GS, et al. Among authors: grek cl. J Invest Dermatol. 2015 Jan;135(1):289-298. doi: 10.1038/jid.2014.318. Epub 2014 Jul 29. J Invest Dermatol. 2015. PMID: 25072595 Free PMC article. Clinical Trial.

4

Topical administration of a connexin43-based peptide augments healing of chronic neuropathic diabetic foot ulcers: A multicenter, randomized trial.

Grek CL, Prasad GM, Viswanathan V, Armstrong DG, Gourdie RG, Ghatnekar GS. Grek CL, et al. Wound Repair Regen. 2015 Mar-Apr;23(2):203-12. doi: 10.1111/wrr.12275. Epub 2015 Apr 29. Wound Repair Regen. 2015. PMID: 25703647 Free PMC article. Clinical Trial.

5

Targeting connexin 43 with α-connexin carboxyl-terminal (ACT1) peptide enhances the activity of the targeted inhibitors, tamoxifen and lapatinib, in breast cancer: clinical implication for ACT1.

Grek CL, Rhett JM, Bruce JS, Abt MA, Ghatnekar GS, Yeh ES. Grek CL, et al. BMC Cancer. 2015 Apr 3;15:296. doi: 10.1186/s12885-015-1229-6. BMC Cancer. 2015. PMID: 25881004 Free PMC article.

6

Evaluation of Lung Metastasis in Mouse Mammary Tumor Models by Quantitative Real-time PCR.

Abt MA, Grek CL, Ghatnekar GS, Yeh ES. Abt MA, et al. Among authors: grek cl. J Vis Exp. 2016 Jan 29;(107):e53329. doi: 10.3791/53329. J Vis Exp. 2016. PMID: 26862835 Free PMC article.

7

Connexin 43, breast cancer tumor suppressor: Missed connections?

Grek CL, Rhett JM, Bruce JS, Ghatnekar GS, Yeh ES. Grek CL, et al. Cancer Lett. 2016 Apr 28;374(1):117-126. doi: 10.1016/j.canlet.2016.02.008. Epub 2016 Feb 13. Cancer Lett. 2016. PMID: 26884256 Review.

8

A Multicenter Randomized Controlled Trial Evaluating a Cx43-Mimetic Peptide in Cutaneous Scarring.

Grek CL, Montgomery J, Sharma M, Ravi A, Rajkumar JS, Moyer KE, Gourdie RG, Ghatnekar GS. Grek CL, et al. J Invest Dermatol. 2017 Mar;137(3):620-630. doi: 10.1016/j.jid.2016.11.006. Epub 2016 Nov 14. J Invest Dermatol. 2017. PMID: 27856288 Free PMC article. Clinical Trial.

9

Targeting the tight junction protein, zonula occludens-1, with the connexin43 mimetic peptide, αCT1, reduces VEGF-dependent RPE pathophysiology.

Obert E, Strauss R, Brandon C, Grek C, Ghatnekar G, Gourdie R, Rohrer B. Obert E, et al. J Mol Med (Berl). 2017 May;95(5):535-552. doi: 10.1007/s00109-017-1506-8. Epub 2017 Jan 28. J Mol Med (Berl). 2017. PMID: 28132078 Free PMC article.

10

Low-Dose Pulsatile Interleukin-6 As a Treatment Option for Diabetic Peripheral Neuropathy.

Cox AA, Sagot Y, Hedou G, Grek C, Wilkes T, Vinik AI, Ghatnekar G. Cox AA, et al. Front Endocrinol (Lausanne). 2017 May 2;8:89. doi: 10.3389/fendo.2017.00089. eCollection 2017. Front Endocrinol (Lausanne). 2017. PMID: 28512447 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

28 results

Search Page